iSERA Lifescienc

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: INE899M01020
  • NSEID:
  • BSEID: 534920
INR
143.90
0.00 (0.00%)
BSENSE

Aug 07, 03:30 PM

BSE+NSE Vol: 10.2 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

10.2 k (253.76%) Volume

Shareholding (Jun 2026)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

58.63%

Why is Covidh Technologies Ltd falling/rising?

09-Aug-2026

As of 08-Aug, the stock price of iSERA Lifesciences Ltd is Rs. 143.90, unchanged from the previous day. Despite a new 52-week high, the stock shows underperformance in its sector, erratic trading, and declining investor participation, suggesting unsustainable growth.

As of 08-Aug, the stock price of iSERA Lifesciences Ltd is currently at Rs. 143.90, with no change from the previous day (0.00%). Despite hitting a new 52-week high today, the stock has shown signs of underperformance, particularly in the context of sector performance, where it underperformed by -0.5%. <BR><BR>Looking at the recent trading activity, there has been erratic trading behavior, as the stock did not trade on one day out of the last 20 days. Additionally, there has been a significant decline in investor participation, with delivery volume dropping by -89.98% against the 5-day average delivery volume. This suggests a lack of interest from investors, which could contribute to the stock's stagnation despite its high price.<BR><BR>In terms of performance metrics, while the stock has shown impressive year-to-date growth of +747.47% and a staggering +4170.03% over the past year, it has also experienced a decline of -72.15% over the past three years. This mixed performance may lead to uncertainty among investors, affecting their trading decisions. <BR><BR>Overall, while the stock has reached a new high, the combination of underperformance relative to the sector, erratic trading patterns, and falling investor participation indicates that the stock may not be rising in a sustainable manner.

View full answer

Which are the latest news on iSERA Lifescienc?

09-Aug-2026

Should I buy, sell or hold Covidh Technologies Ltd?

08-Aug-2026

How big is Covidh Technolog?

11-Jun-2026

Summary could not be generated.

As of 10th June, Covidh Technologies Ltd has a market capitalization of 82.00 Cr, classified as a Micro Cap.<BR><BR>In the latest 4 quarters, the company reported net sales of 19.37 Cr. However, it experienced a loss of 0.08 Cr in net profit during the same period.<BR><BR>The reporting period for the balance sheet data is the latest annual period, but specific values for Shareholder's Funds and Total Assets are unavailable.

View full answer

Who are in the management team of Covidh Technolog?

11-Jun-2026

The management team of Covidh Technolog includes K L Upadhyaya, Uday Chava, Srinivasa Rao Munnangi (Independent Directors), Pittala Sukanya, Naresh Konda (Whole-time Director), Sakshi Mathur (Company Secretary), Sivaiah Kommineni (Additional Independent Director), and Prabhakara Rao Alokam (Director).

The management team of Covidh Technolog includes the following individuals:<BR><BR>1. K L Upadhyaya - Independent Director<BR>2. Uday Chava - Independent Director<BR>3. Srinivasa Rao Munnangi - Independent Director<BR>4. Pittala Sukanya - Director<BR>5. Naresh Konda - Whole-time Director<BR>6. Sakshi Mathur - Company Secretary<BR>7. Sivaiah Kommineni - Additional Independent Director<BR>8. Prabhakara Rao Alokam - Director<BR><BR>If you have any more questions about Covidh Technolog or its management, feel free to ask!

View full answer

Who are the peers of the Covidh Technolog?

11-Jun-2026

Covidh Technolog's peers include Altius Telecom, Embassy Off.REIT, Mindspace Business, Inventurus Knowledge, Sagility, IDream Film, Kalpa Commercial, Focus Suites Solutions, and Amsons Apparels. Notably, IDream Film has the highest 1-year return at 158.03%, while Inventurus Knowledge has the lowest at -2.85%.

Peers: The peers of Covidh Technolog are Altius Telecom, Embassy Off.REIT, Mindspace Busine, Inventurus Knowl, Sagility, IDream Film, Kalpa Commer., Focus Suites Sol, and Amsons Apparels.<BR><BR>Quality Snapshot: Excellent management risk is observed at Inventurus Knowl, while Average management risk is found at Altius Telecom, Embassy Off.REIT, Mindspace Busine, Sagility, and Kalpa Commer. Below Average management risk is noted at Kalpa Commer. Good growth is seen at Inventurus Knowl and Sagility, while Excellent growth is only at Inventurus Knowl. Average growth is found at Mindspace Busine and Kalpa Commer, and Below Average growth is noted at Embassy Off.REIT. The rest of the peers do not qualify for management risk, growth, or capital structure ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is IDream Film at 158.03%, while the peer with the lowest is Inventurus Knowl at -2.85%. Covidh Technolog's 1-year return is not available for comparison. Additionally, Sagility, Focus Suites Sol, and Amsons Apparels have negative six-month returns.

View full answer

What does Covidh Technolog do?

10-Jun-2026

Covidh Technologies Ltd, a Micro Cap company in the IT/ITES sector, reported net sales and net profit of 1 Cr for Q1 2026. The company, originally founded in 1993, has undergone several name changes and currently has a market cap of INR 82 Cr.

Overview: <BR>Covidh Technologies Ltd is engaged in the IT/ITES business and operates within the Miscellaneous industry, classified as a Micro Cap company.<BR><BR>History: <BR>Covidh Technologies Ltd was incorporated on January 27, 1993, originally as 'Lordven Technologies Limited'. The company underwent name changes, first to Aptus Industries Limited in 2011-12 and then to Covidh Technologies Limited on April 21, 2014. The latest quarterly results reported net sales and net profit of 1 Cr for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 82 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 165.00 <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.61 <BR>Return on Equity: -26.00% <BR>Price to Book: -82.38 <BR><BR>Contact Details: <BR>Address: B-2 Plot 797/A Sai Krishna Bld, Road No 36 Jubilee Hills Hyderabad Telangana : 500033 <BR>Tel: 91-040-64643093 <BR>Email: cscovidh@gamil.com <BR>Website: http://www.covidh.co.in

View full answer

Are Covidh Technologies Ltd latest results good or bad?

11-Feb-2026

Covidh Technologies Ltd's latest results are concerning, showing a 69.34% decline in net sales quarter-on-quarter and a net loss, alongside a negative book value and a drastic drop in promoter holdings. The company's financial health indicates significant distress and a high-risk investment profile.

Covidh Technologies Ltd's latest results indicate significant financial distress. The company reported net sales of ₹1.11 crores for June 2019, which marked a staggering 69.34% decline quarter-on-quarter and a 91.95% drop year-on-year. Furthermore, it recorded a net loss of ₹0.06 crores, with negative operating margins and a negative profit after tax margin.<BR><BR>The company's financial health is further illustrated by its negative book value, with a price-to-book ratio of -24.71x, indicating that its liabilities exceed its assets. This situation has led to a complete absence of institutional investor interest, as there are no holdings from foreign institutional investors, mutual funds, or domestic institutional investors.<BR><BR>Additionally, there has been a dramatic decline in promoter holdings, dropping from 100% to just 3.57% in a short period, which is a significant red flag for potential investors. The extreme volatility in stock price, with a 756.85% increase over six months, does not reflect any underlying business improvement, but rather suggests speculative trading in a micro-cap stock with limited liquidity.<BR><BR>Overall, the financial results and the company's trajectory suggest a concerning outlook, characterized by a lack of sustainable profitability, significant operational struggles, and a high-risk investment profile.

View full answer

When is the next results date for Covidh Technologies Ltd?

06-Feb-2026

The next results date for Covidh Technologies Ltd is 10 February 2026.

The next results date for Covidh Technologies Ltd is scheduled for 10 February 2026.

View full answer

How has been the historical performance of Covidh Technolog?

14-Nov-2025

Covidh Technolog has experienced fluctuating financial performance, with net sales declining from INR 33.57 crore in March 2018 to INR 25.69 crore in March 2019, resulting in a profit after tax of -0.04 crore. The company faced rising raw material costs, leading to decreased profitability and negative earnings per share.

Answer:<BR>The historical performance of Covidh Technolog shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Covidh Technolog's net sales have seen a decline from INR 33.57 crore in March 2018 to INR 25.69 crore in March 2019, following a peak of INR 35.89 crore in March 2014. The total operating income mirrored this trend, dropping from INR 33.57 crore in March 2018 to INR 25.69 crore in March 2019. The company faced significant raw material costs of INR 25.03 crore in March 2019, which contributed to total expenditure of INR 25.20 crore, resulting in a slim operating profit of INR 0.49 crore. However, the profit before tax turned negative at INR -0.02 crore in March 2019, leading to a profit after tax of INR -0.04 crore. This marked a notable decline from a profit after tax of INR 0.01 crore in March 2018. The earnings per share also reflected this downturn, falling to -0.04 in March 2019 from 0.01 in the previous year. Overall, the company's financial metrics indicate a challenging period, with decreasing revenues and profitability.

View full answer

Is Covidh Technolog overvalued or undervalued?

27-Oct-2025

As of October 24, 2025, Covidh Technolog is considered risky and overvalued with a PE ratio of 47.09 and negative financial metrics, contrasting sharply with its peers, despite a recent short-term stock performance that outpaced the Sensex.

As of 24 October 2025, Covidh Technolog's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company is currently assessed as overvalued, with a PE ratio of 47.09, a negative Price to Book Value of -6.59, and an EV to EBIT of -8.18. These ratios highlight the company's financial struggles and lack of profitability, which are concerning for potential investors.<BR><BR>In comparison to its peers, Covidh Technolog's valuation metrics are starkly unfavorable. For instance, Altius Telecom, categorized as very attractive, boasts a PE ratio of 55.11, while other peers like Embassy Office REIT and Mindspace Business have PE ratios of 25.69 and 55.87, respectively. The stark contrast in these ratios underscores Covidh Technolog's precarious position in the market. Additionally, while the company's stock has outperformed the Sensex in the short term, with a 1-month return of 30.67% compared to the Sensex's 3.05%, the overall valuation concerns suggest that this momentum may not be sustainable.

View full answer

Who are the top shareholders of the Covidh Technolog?

17-Jul-2025

The top shareholder of Covidh Technolog is Ganapa Narsi Reddy, who owns 100% of the promoter shares. There are no pledged holdings, mutual funds, foreign institutional investors, or significant public shareholders involved.

The top shareholder of Covidh Technolog is Ganapa Narsi Reddy, who holds 100% of the promoter shares. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, there are no significant public shareholders or individual investor holdings reported.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of 136.00% and Operating profit at 0% over the last 5 years
  • The company has a negative book value of Rs 0.11 crore
2

Flat results in Jun 26

3

Risky - Negative Book Value

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Miscellaneous

stock-summary
Market cap

INR 121 Cr (Micro Cap)

stock-summary
P/E

237.00

stock-summary
Industry P/E

32

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.61

stock-summary
Return on Equity

-26.00%

stock-summary
Price to Book

-121.01

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2026)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
409.2%
0%
409.2%
1 Year
4170.03%
0%
4170.03%
2 Years
0%
0%
0.0%
3 Years
-72.15%
0%
-72.15%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Latest dividend: 166.66672025723472 per share ex-dividend date: Sep-20-2013

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.08.2026 Under Regulation 30 Of SEBI

07-Aug-2026 | Source : BSE

Un-Audited Financial Results For The Quarter Ended June 30 2026

07-Aug-2026 | Source : BSE

We are hereby submitting the Unaudited Financial Results of the Company for the quarter ended June 30 2026.

Board Meeting Intimation for The Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Friday 7 August 2026 Inter-Alia To Consider Approve And Take On Record The Unaudited Financial Results Of The Company For The Quarter Ended On J

03-Aug-2026 | Source : BSE

Isera Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter ended on June 30 2026

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

iSERA Lifesciences Ltd has declared 5% dividend, ex-date: 20 Sep 13

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

iSERA Lifesciences Ltd has announced 25:1 rights issue, ex-date: 24 Oct 25

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
136.00%
EBIT Growth (5y)
40.00%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.61
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-3.45%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
237
Industry P/E
32
Price to Book Value
-121.01
EV to EBIT
122.62
EV to EBITDA
122.62
EV to Capital Employed
81.74
EV to Sales
90.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
18.00%
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Dhairyasheel Vasantrao Yadav (13.26%)

Highest Public shareholder

Neville Maneckji (4.31%)

Individual Investors Holdings

35.4%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2026 is -1,600.00% vs -100.00% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.34",
          "val2": "-0.02",
          "chgp": "-1,600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.34",
          "val2": "-0.02",
          "chgp": "-1,600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 50.00% vs 33.33% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.02",
          "val2": "-0.02",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.01",
          "val2": "-0.02",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -222.22% vs 75.68% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.19",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.31",
          "val2": "-0.09",
          "chgp": "-244.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.29",
          "val2": "-0.09",
          "chgp": "-222.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-163.16%",
          "val2": "0.00%",
          "chgp": "-163.16%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 116.67% vs 220.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.36",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.27",
          "val2": "-0.13",
          "chgp": "307.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.26",
          "val2": "0.12",
          "chgp": "116.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "19.85%",
          "val2": "0.00%",
          "chgp": "19.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Jun'26 - YoYstock-summary

Jun'26
Jun'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.34
-0.02
-1,600.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.34
-0.02
-1,600.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

YoY Growth in quarter ended Jun 2026 is 0.00% vs 0.00% in Jun 2025

Direction Arrows
Standalone Net Profit

YoY Growth in quarter ended Jun 2026 is -1,600.00% vs -100.00% in Jun 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.02
-0.02
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.01
-0.02
50.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
Values in Rs Cr.
Net Sales

Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 50.00% vs 33.33% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
0.19
0.00
Operating Profit (PBDIT) excl Other Income
-0.31
-0.09
-244.44%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.29
-0.09
-222.22%
Operating Profit Margin (Excl OI)
-163.16%
0.00%
-163.16%
Values in Rs Cr.
Net Sales

YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -222.22% vs 75.68% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1.36
0.00
Operating Profit (PBDIT) excl Other Income
0.27
-0.13
307.69%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
0.26
0.12
116.67%
Operating Profit Margin (Excl OI)
19.85%
0.00%
19.85%
Values in Rs Cr.
Net Sales

YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2026 is 116.67% vs 220.00% in Mar 2025

stock-summaryCompany CV
About iSERA Lifesciences Ltd stock-summary
stock-summary
iSERA Lifesciences Ltd
Micro Cap
Miscellaneous
Covidh Technologies Limited Limited was formerly incorporated on January 27, 1993 as 'Lordven Technologies Limited'. The name of the Company was changed from Lordven Technologies Limited to Aptus Industries Limited in 2011-12 and again to Covidh Technologies Limited effective 21st April, 2014. Company is engaged into IT/ITES business. The entire Indian IT services industry was challenging in 2010-2011.
Company Coordinates stock-summary
Company Details
B-2 Plot 797/A Sai Krishna Bld, Road No 36 Jubilee Hills Hyderabad Telangana : 500033
stock-summary
Tel: 91-040-64643093
stock-summary
cscovidh@gamil.com
Registrar Details
Aarthi Consultants Pvt Ltd, 1-2-285 , Domalaguda, Hyderabad